Layer 1

New launch tackles opioid constipation

Wyeth Pharmaceuticals has launched its Relistor (methylnaltrexone) treatment for adult patients in palliative care who do not responded to laxative therapy.


The treatment, a peripherally-acting mu-opioid receptor antagonist, has been developed to mitigate the side effects of opioids without affecting pain relief in the central nervous system.


Its use was supported recently by evidence published by the New England Journal of Medicine, which showed patients who received the methylnaltrexone in combination with a laxative were more likely to have a bowel movement compared with those who took the laxative alone.


In use, the treatment improves quality of life for the patient, and reduces the amount of health professionalsÕ time taken managing opioid-related side effects.


http://emc.medicines.org.uk

0 Comments
Login or register to post comments

Job of the week

Pharmacist / Manager
Doncaster, South Yorkshire
To be negotiated + benefits